β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice

• Published in: Physiology & behavior 2014-08, Vol.135, p.119-124
• Main Authors: Bahi, Amine, Al Mansouri, Shamma, Al Memari, Elyazia, Al Ameri, Mouza, Nurulain, Syed M, Ojha, Shreesh
• Format: Article
• Language: English
• Subjects: Adult and adolescent clinical studies; AM630; Animals; Anxiety; Anxiety - drug therapy; Behavior, Animal - drug effects; Behavioral psychophysiology; Biological and medical sciences; CB2 receptors; Depression; Depression - drug therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Fundamental and applied biological sciences. Psychology; Male; Medical sciences; Mice; Miscellaneous; Mood disorders; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychology. Psychophysiology; Psychopathology. Psychiatry; Receptor, Cannabinoid, CB2 - agonists; Sesquiterpenes - pharmacology; Sesquiterpenes - therapeutic use; β-Caryophyllene
• ISSN: 0031-9384; 1873-507X
• DOI: 10.1016/j.physbeh.2014.06.003

Abstract Recent evidence suggests that the cannabinoid receptor subtype 2 (CB2 ) is implicated in anxiety and depression disorders, although few systematic studies in laboratory animals have been reported. The aim of the current experiments was to test the effects of the CB2 receptor potent-selective agonist β-caryophyllene (BCP) in animals subjected to models of anxiolytic- and antidepressant-like effects. Therefore effects of BCP (50 mg/kg) on anxiety were assessed using the elevated plus maze (EPM), open field (OF), and marble burying test (MBT). However for depression, the novelty-suppressed feeding (NSF), tail suspension test (TST), and forced swim tests (FST) were used. Results indicated that adult mice receiving BCP showed amelioration of all the parameters observed in the EPM test. Also, BCP significantly increased the time spent in the center of the arena without altering the general motor activity in the OF test. This dose was also able to decrease the number of buried marbles and time spent digging in the MBT, suggesting an anti-compulsive-like effect. In addition, the systemic administration of BCP reduced immobility time in the TST and the FST. Finally, BCP treatment decreased feeding latency in the NSF test. Most importantly, pre-administration of the CB2 receptor antagonist AM630, fully abrogated the anxiolytic and the anti-depressant effects of BCP. Taken together, these preclinical results suggest that CB2 receptors may provide alternative therapeutic targets for the treatment of anxiety and depression. The possibility that BCP may ameliorate the symptoms of these mood disorders offers exciting prospects for future studies.